Xingya Li

机构：First Affiliated Hospital of Zhengzhou University · ORCID：0009-0005-0711-5702

发表论文 24 篇 · 总被引 262 次 · h-index 8

代表论文

• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials (2025 · Nature Medicine · 被引 47)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial (2025 · Nature Medicine · 被引 30)
• First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial (2025 · Nature Medicine · 被引 20)
• Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B) (2025 · Journal of Clinical Oncology · 被引 17)